Cancún, Mexico — September 14, 2025. The Regenerative Medicine Global Summit 2025, organized by the International Society for Stem Cell Application (ISSCA) — the world’s largest organization dedicated to training physicians in regenerative medicine — successfully took place on September 12–13 at Secrets The Vine Cancún.
With a full house of participants from more than 30 countries, including representatives from Malaysia, Vietnam, Tajikistan, Ghana, South Africa, Japan, the United States, Spain, Italy and multiple nations, Cancún became the epicenter of innovation and collaboration in regenerative medicine.
Leadership Reflections
“This summit proved that regenerative medicine is no longer confined by borders. With physicians and scientists gathered from every continent, we are setting a global standard in how knowledge is shared and therapies are advanced,”
— Dave Christensen, CEO of Global Stem Cells Group (GSCG)
“Our goal is to close the gap between research and clinical practice, giving physicians the tools to deliver the medicine of tomorrow, today. This summit is not only about science; it is about shaping a healthier future for patients,”
— Benito Novas, Founder of ISSCA
“With participants from more than 30 countries, Cancún truly became a hub of regenerative medicine. Between the scientific sessions, the workshops, and the networking opportunities, this event proved Mexico’s growing leadership in biotechnology and medical education,”
— Sarah Barroso, Managing Director, CELLGENIC
Day 1: Scientific Conferences
The first day offered a full agenda of keynote lectures, where global experts presented disruptive insights into the future of regenerative medicine:
- Prof. Mari Dezawa (Japan): MUSE Cells™ and Their Exosomes: The Next Frontier in Immune-Modulating Therapies
ING Agenda Cancun SUMMIT CORT - Dr. Rafael González (USA): Beyond the Hype: The Real-World Evidence Behind NK Cells and Stem Cell Therapies
- Dr. Matt Cook (USA): Precision Ultrasound-Guided Interventions
- Dr. Alan Gaveck (USA): Engineering the Immune System: From Lab to Clinic
- Jason Pencek (USA): Next-Gen Biohacking: Cellular Strategies for Repair, Performance & Healthspan
- Prof. Dato’ Sri Dr. Mike Chan (Malaysia/Europe): Bioregenerative Longevity and Immunomodulation in Anti-Aging Medicine
- Dr. Keith L. March (USA): The Rise of Cell-Free Regenerative Therapies: Clinical-Grade Secretomes as the Future of Medicine
- Dr. Greg Jones (USA): Peptides, Hormones, and Functional Protocols to Reverse Chronic Degeneration
- Dr. Richard Silva (USA): Sports Optimization with Cellular Medicine
- Dr. Jeff Wiegers (USA): Pain Management Reimagined: Biologics, Peptides, and Guided Injections
- Dr. Vincenzo Di Donna (Italy): Organoids and Regenerative Ozone Therapy to Support Stem Cell Therapy
- Prof. Roni Moya (Portugal): Innovations in Regenerative Biomedicine
- Prof. Jonathan Lakey (USA): Advances in Cellular Transplantation
- Dr. Matthew Halpert (USA): Cancer as an Immunological Disorder: A New Weapon in the Fight
The program also featured a select exhibitor area with booths from CELLGENIC, Eleve Health, Immunocine, Cellular Hope Institute, MUSE Cells Innovation, and ISSCA, allowing participants to discover new therapies, devices, and upcoming opportunities.
The day concluded with MedConnect, ISSCA’s signature networking event, hosted at the rooftop of Royalton Chic Cancún. This gathering allowed physicians to connect with peers in their field and foster collaborations in an exclusive setting overlooking the Caribbean.
Day 2: Hands-On Workshops and Certifications
The second day was exclusively reserved for 150 certified participants, divided into five simultaneous workshops designed for practical, hands-on training:
- MUSE Cells Innovation — Prof. Mari Dezawa, Dr. Jeff Wiegers, and Prof. Jonathan Lakey led a session comparing MUSE Cells with mesenchymal stem cells, exploring applications in orthopedics, aesthetics, and immunology.
- NK Cells & Advanced Cellular Therapies — In collaboration with ImmunoSyn at ReHealth’s laboratory, guided by Dr. Rafael González and Dr. Matthew Halpert. Participants later visited the Cellgenic laboratory to observe stem cell manufacturing processes.
- Peptide Therapy Workshop — Jason Pencek and Dr. Greg Jones conducted a comprehensive workshop on therapeutic peptides, dosing strategies, and protocols for longevity, aesthetics, and chronic degeneration.
- Musculoskeletal & Sports Medicine — Directed by Dr. Richard Silva, Dr. Wahid Burad, and Dr. Vincenzo Di Donna, focusing on sports optimization, musculoskeletal regeneration, and longevity protocols.
- Advanced Aesthetics — Presented by Prof. Roni Moya and Prof. Mike Chan, covering exosomes, peptides, PRP, and regenerative aesthetic therapies for facial rejuvenation and tissue regeneration.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a global organization with over 15 years of experience promoting education, research, and certification in regenerative medicine. With presence in more than 20 countries, ISSCA drives the professionalization of the field through international summits, academic programs, and clinical alliances.
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
